secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001493152-23-016160
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma concludes BioNTech mRNA collaboration, plans Phase 3 trial for MAT2203 antifungal
--------------------------------------------------------------------------------

- BioNTech oral mRNA collaboration ended; in vivo oral study showed no activity, but systemic delivery and stability demonstrated.
- Company plans to submit revised Phase 3 trial design for MAT2203 in aspergillosis and other IFIs in Q2 2023.
- Seven patients with IFIs treated under compassionate use; oral MAT2203 showed safety and efficacy in diverse infections.
- Cash position sufficient to fund operations into second half of 2024.
- Expanded collaboration with National Resilience for mRNA/oligonucleotide delivery; initial data expected Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223016160/0001493152-23-016160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223016160/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer